IFW/1626

Patent HE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

JAN 26 2007

Craig W. Lindsley, et al.

Serial No.:

10/572,772

Case No.: 21370P

Filed

March 21, 2006

For

PYRAZOLE MODULATORS OF METABOTROPIC

GLUTAMATE RECEPTORS

Commissioner for Patents

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Date 24 Jan 20

Serial No.: To be assigned

Case No.: 21370P

Page

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

JÆric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: January 24, 2007

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
INFORMATION DISCLOSURE	Application Number	10/572,772	
STAYEMENT BY APPLICANT	Filing Date	March 21, 2006	
	First Named Inventor	<u> </u>	
JANA 2-6 2007	Group Art Unit		
as many sheet is necessary)	Examiner Name		
eet of 1	Attorney Docket Number	21370P	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Kind Code (if known)			Date of Publication of Cited Document MM-DD-YYYY			
		US2006/0235069		Duggan et al.	10/19/2006			

FOREIGN PATENT DOCUMENTS								
Cite No.	Foreign Patent Document Office Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
		WO 2003037274		Atkinson et al	05/08/2003			
		No. Office	Cite Foreign Patent Document	Cite No. Office Number Kind Code (if known)	Cite No. Office Number Kind Code (if known) WO 2003037274 Atkinson et al			

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.